Relationship between Serum Vascular Endothelial Growth Factor-A Levels and Response to Chemotherapy in Cervical Cancer
DOI:
https://doi.org/10.56294/saludcyt2024967Keywords:
Cervical Cancer, VEGF, Neoadjuvant Chemotherapy, Chemotherapy Response, Diameter Of Cervical LesionAbstract
Introduction: cervical cancer ranks second in gynecological cancer worldwide. 62-82 % of cervical cancer patients present at an advanced stage and respond poorly to treatment. Assessment of chemotherapy response requires examination of the biomarker Vascular endothelial growth factor-A (VEGF-A), which is the main regulator of the abnormal angiogenesis process.
Objectives: this study aims to analyze the relationship between serum VEGF-A levels and the response to neoadjuvant chemotherapy in cervical cancer patients.
Methods: this research is Quasi-Experimental, pretest and posttest without control. Total sample: 30 stages IIIB cervical cancer patients underwent a pretest before cisplatin chemotherapy by measuring cervical lesions using ultrasound and serum VEGF-A levels using ELISA. 3 weeks after the third cycle of chemotherapy, a posttest examination is carried out like the pretest examination.
Results: the results showed a significant reduction in serum VEGF-A levels and cervical lesion diameter after chemotherapy (p=0,032), (p=0,000). In response to neoadjuvant chemotherapy, 21 patients responded negatively, and 9 responded positively. High levels of VEGF-A before chemotherapy gave a negative response (p=0,042) and low levels of VEGF-A after chemotherapy gave a positive response (p=0,049).
Conclusions: this study concludes that there is a relationship between high serum VEGF-A levels before chemotherapy with a negative response and low serum VEGF-A levels after chemotherapy with a positive response in cervical cancer patients
References
1. AC Mayasari, “1. Tissue VEGF-Chemoradiation,” Relationship between tissue vascular endothelial growth factor (VEGF) expression and chemoradiation response in cervical cancer patients, vol. 3, pp. 63–69, 2020, doi: 10.18051/JBiomedKes.2020.V3.63-69.
2. IGS Winata, ING Budiana, IM Jawi, and K. Suwiyoga, "Neoadjuvant Chemotherapy in Stages IB3, IIA2 and IIB Cervical Cancer a Narrative Review, "Biomedical and Pharmacology Journal, vol. 15, no. 2, pp. 901–910, 2022, doi: 10.13005/BPJ/2425.
3. Y. Amin, P. Mulawardhana, and D. Erawati, "Demography, Therapy Response and Survival Rate of Stage III-IVA Cervical Cancer Patients Who Received Chemotherapy Followed by Radiotherapy."
4. H. Priyanto, A. Mudigdo, Andrijono, and B. Murti, "Correlation of VEGF-C tissue expression and cervical lesion diameter in cervical cancer patients given neoadjuvant therapy," Bali Medical Journal, vol. 8, no. 1, pp. 299–302, 2019, doi: 10.15562/BMJ .v8i1.1190.
5. F. Armanza, “Serum levels of vascular endothelial growth factor (VEGF) can be used to assess the response to radiation therapy in cervical cancer,” 2014. Online.. Available: www.onlinedoctranslator.com
6. J. Zhang et al., “Prognostic role of vascular endothelial growth factor in cervical cancer: meta-analysis,” 2017. Online.. Available: www.impactjournals.com/oncotarget/
7. S. Srivastava1, “Original article Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer,” 2009. Online.. Available: www.biosciencetrends.com
8. M Sawadaet al., “Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer,” Int J Clin Oncol, vol. 24, no. 12, pp. 1612–1619, Dec. 2019, doi: 10.1007/s10147-019-01495-x.
9. GH Khaimah and S. Muhammad, "Relationship between Histopathological Type and Response to Neoadjuvant Chemotherapy in Stage IB2 and IIA2 Cervical Cancer, "GOLD OBGIN JOURNAL, vol. 3, no. 2, pp. 63–81, Nov. 2019, doi: 10.25077/aogj.3.2.63-81.2019.
10. R. Caf Chemotherapy Tumor Size Based on Examination, "Relationship between Blood Vitamin D Levels in Neoadjuvant." Online.. Available: www.onlinedoctranslator.com
11. JL Alcázar, S. Arribas, JA Mínguez, and M. Jurado, “The Role of Ultrasound in the Assessment of Uterine Cervical Cancer,” Journal of Obstetrics and Gynecology of India, vol. 64, no. 5. Federation of Obstetric and Gynecological Societies of India, pp. 311–316, Oct. 14, 2014. doi: 10.1007/s13224-014-0622-4.
12. H. Priyanto, "Vascular endothelial growth factor-C (VEGF-C), Heparanase and Hypoxia-inducible factors-1a (HIF-1a) as predictors of chemotherapy response in uterine cervical cancer patients, "Dissertation, pp. 1–173, 2018.
13. S. Rosida, R. Sanif, A. Novaliani, and T. Theodorus, "EFFECTIVENESS OF PACLITACXEL-CARBOPLATIN COMBINATION CHEMOTHERAPY BASED ON SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) LEVELS IN EPITHELIAL TYPE OVARIAN CANCER, "Journal of Medicine and Health: Scientific Publication of the Faculty of Medicine, Sriwijaya University, vol. 7, no. 2, pp. 7–13, Apr. 2020, doi: 10.32539/jk.v7i2.9775.
14. K. Zhao, M. Hu, R. Yang, J. Liu, P. Zeng, and T. Zhao, “Decreasing expression of HIF-1α, VEGF-A, and Ki67 with the efficacy of neoadjuvant therapy in locally advanced cervical cancer, ”Medicine (United States), vol. 102, no. 20, p. E33820, May 2023, doi: 10.1097/MD.0000000000033820.
15. PF Zhu, YJ Ou, YH Dong, PZ Xu, and L. Yuan, "Expression of VEGF and HIF-Iα in locally advanced cervical cancer: Potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis, "Onco Targets Ther, vol. 9, pp. 3031–3037, May 2016, doi: 10.2147/OTT.S104142.
16. J. Medicine, S.(Science, T. Medik, A. Arianto, A. Research, and S. Amarwati, “EXPRESSION OF VEGF AND ENDOGLIN AS A PROGNOSTIC FACTOR IN VARIOUS HISTOPATHOLOGICAL DEGREES AND MOLECULAR CLASSIFICATION IN INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE EXPRESSION OF VEGF AND ENDOGLIN AS A PROGNOSTIC FACTOR IN VARIOUS HISTOPATHOLOGICAL DEGREE AND MOLECULAR CLASSIFICATION IN INVASIVE BREAST CARCINOMA OF NO SPECIAL TYPE," vol. 3, 2020.
17. F. Wibisonoet al., “Correlation of VEGF Expression and Microvessel Density With Response to Radiotherapy for Cervical Adenocarcinoma.”
18. KAC Dewi, "The influence of Vascular Endothelial Growth Factors (VEGF) expression post-neoadjuvant chemotherapy on chemotherapy response (huevos), local recurrence, metastasis, and
survival in osteosarcoma patients, "Medical Science Digest, vol. 10, no. 3, Dec. 2019, doi: 10.15562/ism.v10i3.590.
19. A. Minerva Datui, N. Wayan Winarti, L. Putu Iin Indrayani Maker, I. Gusti Ayu Sri Mahendra Dewi, N. Putu Sriwidyani, and I. Made Muliarta, "RELATIONSHIP BETWEEN EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VARIOUS PARAMETERS PATHOLOGY OF SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX AT SANGLAH HOSPITAL DENPASAR, "AUGUST, vol. 10, no. 8, p. 2021, doi: 10.24843.MU.2021.V10.i8.P08.
20. AH Rahmani, AY Babiker, MA Alsahli, SA Almatroodi, and NEOS Husain, "Prognostic significance of vascular endothelial growth factor (VEGF) and Her-2 protein in the genesis of cervical carcinoma, "Open Access Maced J Med Sci, vol. 6, no. 2, pp. 263–268, Feb. 2018, doi: 10.3889/OAMJMS.2018.089.
21. D. Edianto, "VEGF and Cervical Cancer Stage IB – IIA Response after Chemotherapy with Ifosfamide – Cisplatin, "Sumatra Medical Journal, vol. 2, no. 3, pp. 117–122, Sept. 2019, doi: 10.32734/summer.v2i3.1231.
22. LE Minion and KS Tewari, “Cervical cancer – State of the science: From angiogenesis blockade to checkpoint inhibition,” Gynecologic Oncology, vol. 148, no. 3. Academic Press Inc., pp. 609–621, March. 01, 2018. doi: 10.1016/j.ygyno.2018.01.009.
23. Q. Lvet al., “Expression of Angiopoietin and VEGF in cervical cancer and its clinical significance,” Open Life Sci, vol. 13, no. 1, pp. 527–532, 2018, doi: 10.1515/biol-2018-0063.
24. M. Sopoet al., “Expression profiles of VEGF-A, VEGF-D, and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer,” BMC Cancer, vol. 19, no. 1, June. 2019, doi 10.1186/s12885-019-5757-3.
25. Z. Xuet al., “Endostar Synergizes with Radiotherapy to Inhibit Angiogenesis of Cervical Cancer in a Subcutaneous Xenograft Mouse Model,” Frontiers in Bioscience - Landmark, vol. 27, no. 8, Aug. 2022, doi: 10.31083/j.fbl2708238.
Published
Issue
Section
License
Copyright (c) 2024 Milha Nidiya Marni, Pungky Mulawardhana, Puspa Wardhani (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
